Literature DB >> 20488356

Myeloproliferative disorders and the hyperviscosity syndrome.

Bruce D Adams1, Russell Baker, J Abraham Lopez, Susan Spencer.   

Abstract

Myeloproliferative disorders and the serum hyperviscosity syndrome can rapidly manifest with emergent presentations. Hyperviscosity occurs from pathologic elevations of either the cellular or acellular (protein) fractions of the circulating blood. Classic hyperviscosity syndrome presents with the triad of bleeding diathesis, visual disturbances, and focal neurologic signs. Emergency medicine providers should be aware of these conditions and be prepared to rapidly initiate supportive and early definitive management, including plasma exchange and apharesis. Early consultation with a hematologist is essential to managing these complex patients. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID: 20488356     DOI: 10.1016/j.hoc.2010.03.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  4 in total

1.  Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.

Authors:  Baobing Zhao; Yang Mei; Lan Cao; Jingxin Zhang; Ronen Sumagin; Jing Yang; Juehua Gao; Matthew J Schipma; Yanfeng Wang; Chelsea Thorsheim; Liang Zhao; Timothy Stalker; Brady Stein; Qiang Jeremy Wen; John D Crispino; Charles S Abrams; Peng Ji
Journal:  J Clin Invest       Date:  2017-11-20       Impact factor: 14.808

Review 2.  Are MPNs vascular diseases?

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 3.  Diagnosis and Management of Oncologic Emergencies.

Authors:  Sarah Klemencic; Jack Perkins
Journal:  West J Emerg Med       Date:  2019-02-14

4.  Pulmonary hypertension secondary to hyperviscosity in a patient with rheumatoid arthritis and acquired von Willebrand disease: a case report.

Authors:  Thierry Hernández-Gilsoul; Yemil Atisha-Fregoso; Angel G Vargas-Ruíz; Eduardo Rivero-Sigarroa; Guillermo Dominguez-Cherit; Silvio A Namendys-Silva
Journal:  J Med Case Rep       Date:  2013-10-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.